title: Pharmacology of SC-52458, an orally active, nonpeptide angiotensin AT1 receptor antagonist.
abstract: We describe the pharmacologic properties of SC-52458, 5-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl]-2-[2-(1H-tetrazol - 5-ylphenyl)]pyridine, a novel nonpeptide angiotensin II (AII) receptor antagonist. SC-52458 was a potent inhibitor of [125I]AII binding to AT1 receptors in rat adrenal cortex and uterine smooth muscle membranes (IC50 values of 2.8 and 6.9 nM, respectively). Contraction of rabbit aortic rings by AII was antagonized by SC-52458 in a competitive and reversible manner (pA2 of 8.18). SC-52458 had no effect on the activity of angiotensin converting enzyme (ACE) or renin in vitro. In normotensive rats, administration of SC-52458, either intravenously (i.v.) or by gavage, inhibited the pressor response to AII. Daily treatment with SC-52458 at 20, 30, and 50 mg/kg by gavage for 4 days decreased blood pressure (BP) in conscious, spontaneously hypertensive rats (SHR). Further studies in renal-artery ligated rats and sodium-deficient dogs demonstrated that oral administration of SC-52458 decreased BP and that this activity was correlated with significant plasma levels of the compound. SC-52458 is an orally active, competitive AT1-receptor antagonist with antihypertensive properties.
authors.affiliation: Department of Cardiovascular Diseases Research, St. Louis, MO 63167.
authors.forename: G M
authors.initials: GM
authors.lastname: Olins
authors.forename: V M
authors.initials: VM
authors.lastname: Corpus
authors.forename: S T
authors.initials: ST
authors.lastname: Chen
authors.forename: E G
authors.initials: EG
authors.lastname: McMahon
authors.forename: M A
authors.initials: MA
authors.lastname: Palomo
authors.forename: D E
authors.initials: DE
authors.lastname: McGraw
authors.forename: G J
authors.initials: GJ
authors.lastname: Smits
authors.forename: C L
authors.initials: CL
authors.lastname: Null
authors.forename: M A
authors.initials: MA
authors.lastname: Brown
authors.forename: S E
authors.initials: SE
authors.lastname: Bittner
mesh_terms: D000284:Administration, Oral; D000302:Adrenal Cortex / Q000187:drug effects / Q000378:metabolism; D000804:Angiotensin II / Q000037:antagonists & inhibitors* / Q000378:metabolism / Q000494:pharmacology; D057911:Angiotensin Receptor Antagonists; D000818:Animals; D001665:Binding Sites; D001794:Blood Pressure / Q000187:drug effects*; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006973:Hypertension / Q000188:drug therapy / Q000503:physiopathology; D066298:In Vitro Techniques; D008297:Male; D009130:Muscle, Smooth / Q000187:drug effects / Q000378:metabolism; D007703:Peptidyl-Dipeptidase A / Q000378:metabolism; D011725:Pyridines / Q000494:pharmacology*; D011817:Rabbits; D051381:Rats; D011918:Rats, Inbred SHR; D011945:Receptors, Angiotensin / Q000378:metabolism; D012083:Renin / Q000097:blood; D013777:Tetrazoles / Q000494:pharmacology*; D014599:Uterus / Q000378:metabolism
chemical_list: D057911:Angiotensin Receptor Antagonists; D011725:Pyridines; D011945:Receptors, Angiotensin; D013777:Tetrazoles; C084927:forasartan; D000804:Angiotensin II; D007703:Peptidyl-Dipeptidase A; D012083:Renin